Company: DMAAR
Filing Date: 2025-11-17
Form Type: NT 10-Q
Source: 0001213900-25-111208
Chunk: 1

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-17
Form: NT 10-Q
Chunk 1
---
 the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|   | -c | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.                                                                                                                                                                                                                                                                                                                                                                |

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K,
20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

We could not timely file our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion prior to the due date of the report.

PART IV – OTHER INFORMATION

| (1) | Name and telephone number of person to contact in regard to this notification |

| Lynn Stockwell |     |       -954 |     | 870-3099          |
| (Name)         |     | -Area Code |     | -Telephone Number |

| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | ☒ Yes ☐ No |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?                                                                                              | ☐ Yes ☒ No |

| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |

<div align='center'>2

Drugs Made In America Acquisition Corp.

(Name of Registrant as Specified in Charter)</div>

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

| Date : November 14, 2025 | By: | /s/ Lynn Stockwell |                         |